Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
VALENCIA, Calif., Aug. 25, 2016 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced that the United States District Court for the Central District of California has dismissed the class action that was pending against MannKind Corporation and two of its executives. The Court granted the defendants’ motion to dismiss the plaintiffs’ amended class action complaint without leave to amend, thereby closing the case. The plaintiffs can appeal the decision within 30 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected]
